Positron emission tomography in the management of patients with indolent non-Hodgkin's lymphoma.

This publication has 11 references indexed in Scilit:

• Frequent Impact of [18F]Fluorodeoxyglucose Positron Emission Tomography on the Staging and Management of Patients with Indolent Non-Hodgkin's Lymphoma
  Clinical Lymphoma, 2003
• Utility of FDG-PET scanning in lymphoma by WHO classification
  Blood, 2003
• Positron Emission Tomography in Non-Hodgkin's Lymphoma (NHL): Relationship Between Tracer Uptake and Pathological Findings, Including Preliminary Experience in the Staging of Low-Grade NHL
  Clinical Lymphoma, 2002
• Prognostic value of positron emission tomography in the evaluation of post‐treatment residual mass in patients with Hodgkin's disease and non‐Hodgkin's lymphoma
  British Journal of Haematology, 2001
• Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease
  Annals of Hematology, 2001
• Positron Emission Tomography (PET) for Staging Low-Grade Non-Hodgkin's Lymphomas (NHL)
  Cancer Biotherapy and Radiopharmaceuticals, 2001
• Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin’s lymphoma (NHL)
  Annals of Oncology, 2001
• Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography
  European Journal of Nuclear Medicine and Molecular Imaging, 1998
• Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
  Radiology, 1997
• Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT.
  Radiology, 1994